Activity of Chitosans in combination with antibiotics in Pseudomonas aeruginosa

International Journal of Biological Sciences

Volumn 5, Issue 2, 2009, Pages 153-160

  Tin, San ^a,b   Sakharkar, Kishore R ^a,c   Lim, Chu Sing ^a,b   Sakharkar, Meena K ^a,b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c OmicsVista   (Singapore)

Author keywords

Additive; Chitin; Chitosan; Combination therapy; Drug resistance; Synergy

Indexed keywords

ACETIC ACID; ANTIBIOTIC AGENT; CEFTRIAZONE; CHITOSAN DERIVATIVE; CHITOSAN OLIGOSACCHARIDE; CHLORAMPHENICOL; CLARITHROMYCIN; DEACETYLATED MEDIUM MOLECULAR WEIGTH CHITOSAN; HIGH MOLECULAR WEIGHT CHITOSAN; LOW MOLECULAR WEIGHT CHITOSAN; MEDIUM MOLECULAR WEIGHT CHITOSAN; OFLOXACIN; POLYMYXIN B; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; CHITOSAN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SULFAMETHOXAZOLE;

EID: 62749186123     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.5.153     Document Type: Article

References (36)

1. Lee YC, Ahn BJ, Jin JS, et al. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu. Korea. J Microbiol. 2007; 45:358-363.
2. Falagas ME, Bliziotis IA, Kasiakou SK, et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect. Dis, 2005; 5: 24-30.
3. Bosso JA. The antimicrobial armamentarium: evaluating current and future treatment options. Pharmacotherapy. 2005; 25: 55S-62S.
4. Ling TKW, Xiong J, Yu Y, et al. Multicenter antimicrobial susceptibility survey of Gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China. Antimicrob Agents Chemother. 2006; 50: 374-378.
5. George ME, Robert C, Moellering JR. Antimicrobial Combinations. Antibiotics in Laboratory Medicine 4th ed. Baltimore: The Williams & Wilkins Co. 1996.
6. Dawis MA, Isenberg HD, France KA, et al. In vitro activity of gatifloxacin alone and in combination with cefepim, meropenem, piperacillin and gentamicin against multidrug-resistant organisms. J.Antimicrob.Chemother. 2003; 51:1203-1211.
7. Monden K, Ando E, Iida M, et al. Role of fosfomycin in synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J.Infect.Chemother. 2002; 8: 218-226.
8. Cernohorska L, Votava M. Antibiotic Synergy against Biofilm-Forming Pseudomonas aeruginosa. Folia Microbiol. 2008; 53: 57-60.
9. Neu HC. Synergy and antagonism of combinations of quinolones. European Journal of Clinical Microbiology and Infectious Diseases. 1991; 10: 255-61.
10. Donabedian H, Andriole VT. Synergy of vancomycin with penicillins and cephalosporins against Pseudomonas, Klebsiella and Serratia. Yale Journal of Biology and Medicine. 1977; 50: 165-176.
11. Wise R. Antimicrobial resistance: paradox, actions and economics. Journal of Antimicrobial Chemotherapy. 2006; 57: 1024-1025.
12. Gould MI. Antibiotic policies to control hospital-acquired infection. Journal of Antimicrobial Chemotherapy. 2008; 61: 763-765.
13. Amyes SG., Walsh FM, Bradley JS. Best in class: a good principle for antibiotic usage to limit resistance development? Journal of Antimicrobial Chemotherapy. 2007; 59: 825-826.
14. George A, Roberts F. Chitin Chemistry, 1st ed. London: Macmillan, 1992.
15. Arai K, Kinumaki T, Fujita T. Toxicity of chitosan. Bull Tokai Reg Fish lab. 1968; 43: 89-94.
16. Qin CQ, Li HR, Xiao Q, Liu Y, Zhu JC, Du YM. Water-solubility of chitosan and its antimicrobial activity. Carbohydrate Polymers. 2006; 63: 367-374.
17. Chen Y M, Chung YC, Wang LW, Chen KT, Li SY. Antibacterial activity of chitosan- based matrixes on oral pathogens. J. Environ Sci Health A Tox Hazard Subst Environ Eng. 2002; 37: 1379-1390.
18. No HK, Park NY, Lee SH, Meyers SP. Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. International Journal of Food Microbiology. 2002; 74: 65-72.
19. Liu H, Bao JG, Du YM, Zhou X, and Kennedy JF. Effect of ultrasonic treatment on the biochemphysical properties of chitosan. Carbohydrate Polymers. 2006; 64: 553-559.
20. Rhoades J, Roller S. Antimicrobial Actions of Degraded and Native Chitosan against Spoilage Organisms in Laboratory Media and Foods. Applied and Environmental Microbiology. 2000; 66: 80-86.
21. Pittler M H, Abbot NC, Harkness EF, Ernet E. Randomised, double - blind trial of chitosan for body weight reduction. Eur J Clin Nutr. 1999; 53: 379-381
22. Decker E-M, von Ohle C., Weiger R, Wiech I, Brecx M. A synergistic chlorhexidine/chitosan combination for improved antiplaque strategies. Journal of Periodontal Research. 2005; 40: 373-377.
23. Tre-Hardy M, Vanderbist F, Traore H, and Devleeschouwer MJ. In vitro activity of antibiotic combinations against Pseudomonas aeruginosa biofilm and planktonic cultures. International Journal of Antimicrobial Agents. 2008;:329-336.
24. Ikinci G, Senel S, Akincibay H, Kas S, Ercis S, Wilson CG, Hincal AA. Effect of chitosan on a periodontal pathogen Porphyromonas gingivalis. International Journal of Pharmaceutics. 2002; 235: 121-127.
25. Aksungur P, Sungur A, Unal S, Iskit AB, Squier CA, Senel S. Chitosan delivery systems for the treatment of oral mucositis: in vitro and in vivo studies. Journal of Controlled Release 2004; 98: 269-279.
26. Senel S, Ikinci G, Kas S, Yousefi-Rad A, Sargon MF, Hincal AA. Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. International Journal of Pharmaceutics. 2000; 193: 197-203.
27. Anil KA, Stevens WF. Chitosan-alginate multilayer beads for controlled release of ampicillin. International Journal of Pharmaceutics. 2005; 290: 45-54.
28. Di Colo G, Zambito Y, Burgalassi S, Nardini I, Saettone MF. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. International Journal of Pharmaceutics. 2004; 273: 37-44.
29. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, and Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterization. European Journal of Pharmaceutics and Biopharmaceutics. 2008; 68: 513-525.
30. Richard S, Lynn S-M, Avery CG. Antimicrobial susceptibility testing protocols. New York: CRC Press, 2007.
31. Mattheus FA Goosen. Applications of chitin and Chitosan. USA: Technomic Publishing Company Inc. 1997.
32. Rúnarsson ÖV, Holappa J, et al. Antibacterial activity of methylated chitosan and chitooligomer derivatives: synthesis and structure activity relationships. European Polymer Journal. 2007; 43: 2660-2671.
33. Holappa J, Hjálmarsdóttir M., Másson M., Rúnarsson Ö V, Asplund T.Soininen P, Nevalainen T, Järvinen T. Effects of pH and Degree of Substitution on the Antimicrobial Activity of Chitosan N-Betainates. Carbohydrate Polymers. 2006; 65(1): 114-118.
34. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. International Journal of Antimicrobial Agents. 1999; 11: 7-12.
35. Raafat D.,von Bargen K., Haas A, and Sahl H. Insight into the mode of action of Chitosan as an Antibacterial Compound. Applied and Environmental Microbiology. 2008; 74: 3764-3773.
36. Helander I M, E-L Nurmiaho-Lassila , Ahvenainen R , Rhoades J, Roller S. Chitosan disrupts the barrier properties of the outer membrane of Gram-negative bacteria. International Journal of Food Microbiology. 2001; 71: 235-244